Contemporary oncology (Poznan, Poland)最新文献_第2页

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. BRAF和MEK抑制剂在黑色素瘤患者免疫治疗时代的应用。

IF 1.8

Contemporary oncology (Poznan, Poland) Pub Date : 2018-03-01 Epub Date: 2018-03-05 DOI: 10.5114/wo.2018.73890

Jacek Mackiewicz, Andrzej Mackiewicz

{"title":"BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients.","authors":"Jacek Mackiewicz, Andrzej Mackiewicz","doi":"10.5114/wo.2018.73890","DOIUrl":"https://doi.org/10.5114/wo.2018.73890","url":null,"abstract":"The treatment landscape in advanced melanoma is changing dramatically with the approval of new drugs. Vemurafenib was the first approved targeted agent for the treatment of BRAF-mutant advanced melanoma. However, treatment with a BRAF inhibitor is linked with acquired resistance occurring in half of the patients after approximately six months. Combination of MEK and BRAF inhibitor therapy results in extension of the time to resistance, translating into longer overall survival of treated patients. Similar clinical benefits are observed with therapy using antibodies against immune-checkpoint inhibitors in the same patient population. Due to the fact that results of randomised studies comparing these two treatment strategies back to back have not been presented yet, the best first and second line treatment option in patients with BRAF-mutant melanoma is unknown. Currently, phase 3 studies are also evaluating the efficacy of targeted therapy combined with immunotherapy in patients with BRAF-mutant and BRAF wild-type advanced melanoma. Identifying a biomarker for the selection of patients benefiting most from the treatment will be crucial for further survival improvement in patients with advanced melanoma.","PeriodicalId":520599,"journal":{"name":"Contemporary oncology (Poznan, Poland)","volume":" ","pages":"68-72"},"PeriodicalIF":1.8,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/wo.2018.73890","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35986109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 57

The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment. 缺氧在肿瘤微环境中形成促血管生成和免疫抑制细胞募集中的作用。

IF 1.8

Contemporary oncology (Poznan, Poland) Pub Date : 2018-03-01 Epub Date: 2018-03-05 DOI: 10.5114/wo.2018.73874

Salem Chouaib, Viktor Umansky, Claudine Kieda

{"title":"The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment.","authors":"Salem Chouaib, Viktor Umansky, Claudine Kieda","doi":"10.5114/wo.2018.73874","DOIUrl":"https://doi.org/10.5114/wo.2018.73874","url":null,"abstract":"Hypoxia characterizes growing tumors and contributes significantly to their aggressiveness. Hypoxia-inducible factors (HIFs 1 and 2) are stabilized and act differentially as transcription factors on tumor growth and are responsible for important cancer hallmarks such as pathologic angiogenesis, cellular proliferation, apoptosis, differentiation and genetic instability as well as affecting tumor metabolism, tumor immune responses, invasion and metastasis. Taking into account the tumor tissue as a whole and considering the interplay of the various partners which react with hypoxia in the tumor site lead to reconsideration of the treatment strategies. Key limitations of treatment success result from the adaptation to the hypoxic milieu sustained by tumor anarchic angiogenesis. This raises immune tolerance by influencing the recruitment of immunosuppressive cells as bone marrow derived suppressor cells (MDSC) or by impairing the infiltration and killing of tumor cells by cytotoxic cells at the level of the endothelial cell wall of the hypoxic tumor vessels, as summarized in the schematic abstract.","PeriodicalId":520599,"journal":{"name":"Contemporary oncology (Poznan, Poland)","volume":" ","pages":"7-13"},"PeriodicalIF":1.8,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/wo.2018.73874","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35986653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 29

The emerging role of plasma exosomes in diagnosis, prognosis and therapies of patients with cancer. 血浆外泌体在癌症患者诊断、预后和治疗中的新作用。

IF 1.8

Contemporary oncology (Poznan, Poland) Pub Date : 2018-03-01 Epub Date: 2018-03-05 DOI: 10.5114/wo.2018.73882

Theresa L Whiteside

引用次数: 42

Clinical and immunological correlates of long term survival in glioblastoma. 胶质母细胞瘤长期生存的临床和免疫学相关性。

IF 1.8

Contemporary oncology (Poznan, Poland) Pub Date : 2018-03-01 Epub Date: 2018-03-05 DOI: 10.5114/wo.2018.73893

Bartosz Czapski, Szymon Baluszek, Christel Herold-Mende, Bozena Kaminska

{"title":"Clinical and immunological correlates of long term survival in glioblastoma.","authors":"Bartosz Czapski, Szymon Baluszek, Christel Herold-Mende, Bozena Kaminska","doi":"10.5114/wo.2018.73893","DOIUrl":"https://doi.org/10.5114/wo.2018.73893","url":null,"abstract":"Glioblastoma (GBM) is the most common and most aggressive type of primary brain tumour in adults. It represents 54% of all gliomas and 16% of all brain tumours (Ostrom et al. 2016). Despite surgery and treatment with radiotherapy plus an oral alkylating agent, temozolomide (TMZ), tumours invariably recur, and the patient survival is an average of ~14-16 months. In this review we summarise the current understanding of multiple factors that may affect survival of patients with GBMs. In particular, we discuss recent advancements in surgery and detection of genomic-based markers with prognostic values, such as IDH1/2 mutations, MGMT gene promoter methylation, and TERT gene promoter alterations. We address the issue of tumour heterogeneity and evolution that may result in different parts of the same tumour exhibiting different GBM subtypes and in subtype switching, which may restrict the usefulness of the expression-based classification as a prognostic marker before relapse. The determinants of long-term survival in patients with IDH1/2wt GBM, beyond MGMT promoter methylation, remain to be identified, and even the absence of both IDH1/2 mutations and MGMT promoter methylation does not preclude long-term survival. These findings suggest that host-derived factors, such as immune system responsiveness may contribute to long-term survival in such patients. We report the results of high-throughput approaches, suggesting links between long-term survival and enhanced immune-related gene expression. The further search for new gene candidates, promoter methylation status, and specific features of host immunity should provide prognostic biomarkers for the evaluation of survival of IDH1 wild-type/non-G-CIMP GBMs.","PeriodicalId":520599,"journal":{"name":"Contemporary oncology (Poznan, Poland)","volume":" ","pages":"81-85"},"PeriodicalIF":1.8,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/wo.2018.73893","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35986110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Personalized medicine in oncology. New perspectives in management of gliomas. 肿瘤学个体化医疗。胶质瘤治疗的新观点。

IF 1.8

Contemporary oncology (Poznan, Poland) Pub Date : 2018-03-01 Epub Date: 2018-03-05 DOI: 10.5114/wo.2018.73872

Justyna Gil, Izabela Laczmanska, Karolina A Pesz, Maria M Sasiadek

引用次数: 10